A Section 1 scientific trial of Qnovia’s RespiRx handheld inhalable nicotine alternative remedy (NRT) revealed cigarette-comparable nicotine supply with favorable security profile.
Qnovia Inc reported optimistic outcomes from its Section 1 scientific trial evaluating the security and efficacy of RespiRx, a handheld inhalable nicotine alternative remedy (NRT) designed to assist people who smoke give up.
The scientific trial was carried out in 2025 on 25 wholesome adults and aimed to establish the pharmacokinetic profile of RespiRx in relation to cigarettes and Nicotrol Inhaler, a buccal NRT whose manufacturing was discontinued in 2023.
Key findings embrace:
- A decrease plasma nicotine publicity than cigarettes, whereas sustaining efficient craving aid with out extreme dosing
- Delivers cigarette-like nicotine uptake, a vital issue for efficient craving management and smoking cessation. Reaching peak blood ranges in 7 minutes with simply 10 puffs (Cmax 8.7 ng/mL), demonstrating a Tmax comparable to flamable cigarettes of ~6 minutes, considerably outperforming approved legacy nicotine alternative therapies
- Significant discount in urge-to-smoke scores, suggesting efficient satiation
- No severe negative effects or antagonistic occasions; solely a average cough was reported
The research employed a randomized, open-label, three-way crossover design for grownup people who smoke. Individuals obtained single doses of RespiRx, a standard cigarette and Nicotrol Inhaler in a randomized trend. This allowed researchers to successfully consider and evaluate peak nicotine ranges (Cmax), nicotine publicity over time (Tmax), the speed at which nicotine reached the bloodstream (AUC), and contributors’ urge to smoke rating.
The corporate says its ultraportable vibrating mesh nebulizer is poised to be the primary protected and efficient NRT innovation launched to the market in over 20 years.
“We’re very inspired by the outcomes of the first-in-human FDA trial of RespiRx,” mentioned Mario Danek, founder and CEO of Qnovia. “The findings present that our novel nicotine supply methodology — by way of a cool mist, with none heating or combustion — matches the pace and habit-loop of smoking and vaping with out the carcinogens. As the primary main NRT innovation in twenty years, and first-ever really inhaled Investigational New Drug-cleared NRT, RespiRx is uniquely positioned to globally drive in the direction of a smoke-free era and meaningfully scale back the burden of smoking-related illness.”
